These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 26732039)

  • 1. Considering GH replacement for GH-deficient adults with a previous history of cancer: a conundrum for the clinician.
    Yuen KC; Heaney AP; Popovic V
    Endocrine; 2016 May; 52(2):194-205. PubMed ID: 26732039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone replacement in patients with a history of malignancy: a review of the literature and best practice for offering treatment.
    Yuen KC; Popovic V
    Expert Rev Endocrinol Metab; 2015 May; 10(3):319-326. PubMed ID: 30298774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: data from KIMS (Pfizer International Metabolic Database).
    Popovic V; Mattsson AF; Gaillard RC; Wilton P; Koltowska-Häggström M; Ranke MB
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4449-54. PubMed ID: 20610598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults.
    van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    Pituitary; 2016 Aug; 19(4):381-90. PubMed ID: 27048484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in the risk of neoplasia in GH deficiency.
    Pekic S; Stojanovic M; Popovic V
    Best Pract Res Clin Endocrinol Metab; 2017 Feb; 31(1):35-47. PubMed ID: 28477731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth Hormone's Links to Cancer.
    Boguszewski CL; Boguszewski MCDS
    Endocr Rev; 2019 Apr; 40(2):558-574. PubMed ID: 30500870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acromegaly induced by growth hormone replacement therapy.
    Karges B; Pfäffle R; Boehm BO; Karges W
    Horm Res; 2004; 61(4):165-9. PubMed ID: 14707471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reviewing the safety of GH replacement therapy in adults.
    Stochholm K; Johannsson G
    Growth Horm IGF Res; 2015 Aug; 25(4):149-57. PubMed ID: 26117668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does growth hormone cause cancer?
    Jenkins PJ; Mukherjee A; Shalet SM
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):115-21. PubMed ID: 16430706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long-term growth hormone replacement in adults with growth hormone deficiency following cure of acromegaly: a KIMS analysis.
    Tritos NA; Johannsson G; Korbonits M; Miller KK; Feldt-Rasmussen U; Yuen KC; King D; Mattsson AF; Jonsson PJ; Koltowska-Haggstrom M; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2014 Jun; 99(6):2018-29. PubMed ID: 24694339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth Hormone Deficiency and Treatment in Childhood Cancer Survivors.
    Pollock NI; Cohen LE
    Front Endocrinol (Lausanne); 2021; 12():745932. PubMed ID: 34745010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
    Drake WM; Coyte D; Camacho-Hübner C; Jivanji NM; Kaltsas G; Wood DF; Trainer PJ; Grossman AB; Besser GM; Monson JP
    J Clin Endocrinol Metab; 1998 Nov; 83(11):3913-9. PubMed ID: 9814468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer risk following growth hormone use in childhood: implications for current practice.
    Ogilvy-Stuart AL; Gleeson H
    Drug Saf; 2004; 27(6):369-82. PubMed ID: 15144231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.
    van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GH therapy and cancer risk in hypopituitarism: what we know from human studies.
    Pekic S; Popovic V
    Eur J Endocrinol; 2013 Nov; 169(5):R89-97. PubMed ID: 23935131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Night sleep EEG and daytime sleep propensity in adult hypopituitary patients with growth hormone deficiency before and after six months of growth hormone replacement.
    Schneider HJ; Oertel H; Murck H; Pollmächer T; Stalla GK; Steiger A
    Psychoneuroendocrinology; 2005 Jan; 30(1):29-37. PubMed ID: 15358440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with Growth Hormone for Adults with Growth Hormone Deficiency Syndrome: Benefits and Risks.
    Díez JJ; Sangiao-Alvarellos S; Cordido F
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults.
    Feldt-Rasmussen U; Wilton P; Jonsson P; ;
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S51-8. PubMed ID: 15135778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
    Chung TT; Drake WM; Evanson J; Walker D; Plowman PN; Chew SL; Grossman AB; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):274-9. PubMed ID: 16117814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acromegaly, growth hormone and cancer risk.
    Renehan AG; Brennan BM
    Best Pract Res Clin Endocrinol Metab; 2008 Aug; 22(4):639-57. PubMed ID: 18971124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.